000			04421nam a2200421 i 4500
999			_c361354 _d361354
001			361354
003			ES-MaUEC
005			20230102121347.0
006			a|||| o|||| 00| 0
007			cr nn nnnaamaa
008			211115s2021 sz | o |||| 0|eng d
020			_a9783030851613
024	7		_a10.1007/978-3-030-85161-3 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRL74 _b2021 EB
245	0	0	_aPathogenesis of Systemic Lupus Erythematosus : _bInsights from Translational Research _cedited by Alberta Hoi
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XXI, 178 páginas) _b36 ilustraciones, 24 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aBiomedical and Life Sciences (SpringerNature-11642)
490	0		_aBiomedical and Life Sciences (R0) (SpringerNature-43708)
505	0		_aAdvances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.
520	3		_aThe scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.
988			_aSpringer_BiomedLife_2021
650		7	_2embne _9168912 _aPiel _xEnfermedades
650		7	_2embne _aInmunología _9138330
700	1		_aHoi, Alberta _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _9680722
776	0	8	_iPrinted edition: _z9783030851606
776	0	8	_iPrinted edition: _z9783030851620
776	0	8	_iPrinted edition: _z9783030851637
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-85161-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2022 _dz _eb _zSI